Valuation: TransCode Therapeutics, Inc.

Market Cap 20.07M 18.28M 16.85M 15.32M 28.75M 1.86B 30.21M 205M 81.49M 1.02B 75.31M 73.72M 3.19B P/E 2024
-0.07x
P/E 2025 -0.13x
Enterprise Value 2.26M 2.06M 1.9M 1.72M 3.24M 209M 3.4M 23.07M 9.17M 114M 8.48M 8.3M 359M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
98.26%
Yield 2024 *
-
Yield 2025 -

Last Transcript: TransCode Therapeutics, Inc.

1 day-10.77%
1 week-12.12%
Current month-28.83%
1 month-30.12%
3 months-59.58%
6 months-81.03%
Current year-83.02%
1 week 1.01
Extreme 1.01
1.53
1 month 1.01
Extreme 1.01
1.91
Current year 1.01
Extreme 1.01
12.6
1 year 1.01
Extreme 1.01
12.6
3 years 1.01
Extreme 1.01
17,245.52
5 years 1.01
Extreme 1.01
2,313,719.69
10 years 1.01
Extreme 1.01
5,174,452.99
Manager TitleAgeSince
Chief Executive Officer 67 06/10/2025
Chief Tech/Sci/R&D Officer 52 01/10/2021
Director of Finance/CFO 61 10/09/2026
Director TitleAgeSince
Chairman 67 18/02/2021
Director/Board Member 54 20/12/2020
Director/Board Member 67 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Free

Chief Executive Officer

185,000 1.0927%
8/3/26 A ConversionCompany 13,834,441 81.7120%
7/27/26 A OtherCompany 300,040 1.7722%
Change 5-day change 1-year change 3-year change Capi.($)
-10.77%-12.12%-86.57%-99.99% 20.07M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -2.31%-2.31%+21.10%+152.49% 40B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.15%

Financials

2024 2025
Net sales - -
Net income -16.75M -15.26M -14.06M -12.79M -24M -1.55B -25.22M -171M -68.02M -847M -62.86M -61.54M -2.66B -34.66M -31.57M -29.09M -26.46M -49.64M -3.21B -52.17M -354M -141M -1.75B -130M -127M -5.5B
Net Debt -5.77M -5.26M -4.84M -4.41M -8.27M -535M -8.69M -58.97M -23.44M -292M -21.66M -21.2M -916M -17.81M -16.22M -14.95M -13.6M -25.51M -1.65B -26.81M -182M -72.32M -901M -66.84M -65.43M -2.83B
Projected Income Statement - Annual - TransCode Therapeutics, Inc.
Logo TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Employees
12
Date Price Change Volume
20/11/26 $1.160 -10.77% 60,672
19/11/26 $1.300 -3.35% 17,105
18/11/26 $1.345 -4.61% 18,086
17/11/26 $1.410 +4.44% 36,749
16/11/26 $1.350 +2.27% 50,416

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - TransCode Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RNAZ Stock